NCT02432235 (Clinical Trial/ ADCT-301)

Study Title
Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma (NCT02432235)

Trial Description
This study evaluates ADCT-301 in patients with relapsed/refractory Non-Hodgkin or Hodgkin lymphoma. Patients will participate in a dose-escalation phase (Part 1) and receive escalating doses of ADCT-301 every 3 weeks. In Part 2 of the study, patients will receive a recommended dose of ADCT-301 every 3 weeks.
This trial is sponsored by ADC Therapeutics SARL. [1]

Study Data

• Condition: 
  • Hodgkin Lymphoma
  •  Non-Hodgkin Lymphoma
• Interventions:
  • Drugs used in this trial
    • ADCT-301 (ADC Therapeutics SARL)
• Phase: I
• Estimated Enrollment: 140
• Start: June 2015
• Estimated Primary Completion: June 2018
• Last updated: October 2017

Study Schematic

Click here to Return to Drug map

Last Editorial review: January 2018
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.